You are here

Mayo Clinic Finds <i>C. Diff</i> Infection Risk Increases With Antihistamine Use to Treat Stomach Acid

Authors recommend judicious use of histamine 2 receptor antagonists (Mar. 27)

Patients receiving antihistamines to suppress stomach acid are at greater risk of infection from Clostridium difficile, a common cause of diarrhea, particularly in health care settings, according to Mayo Clinic researchers. The new study focused on histamine 2 receptor antagonists. The researchers found no significant risk for people taking over-the-counter antihistamine drugs, however. The findings were published online in PLoS One.

The researchers reviewed 35 observations based on 33 separate studies involving C. difficile and antihistamines used for stomach acid suppressive therapy. A clear association was found between the use of histamine 2 receptor antagonists and C. difficile infection. The investigators say this association was especially pronounced in and caused the greatest risk for hospitalized patients receiving antibiotics.

“It's not clear why these antihistamines increase the risk of C. diff infection, because gastric acid does not affect C. diff spores,” said senior author Larry Baddour, MD. “However, it may be that vegetative forms of C. diff, which are normally killed by stomach acid, survive due to the use of stomach acid suppressors and cause infection.”

According to the investigators, the study results highlight the need for judicious use of histamine 2 receptor antagonists in hospitalized patients, and suggest that reducing the use of these drugs could significantly reduce the risk of C. difficile infections.

Source: Mayo Clinic; March 27, 2013.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival